Sanofi US
270 Albany Street
Cambridge
Massachusetts
02139
United States
Tel: 800-446-6267
Website: http://www.sanofi.us/
About Sanofi US
Sanofi, a diversified global healthcare leader, discovers, develops, and distributes therapeutic solutions to improve the lives of everyone. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With more than 100,000 dedicated professionals in more than 100 countries, Sanofi is devoted to advancing healthcare around the world. Sanofi US, with headquarters in Bridgewater, New Jersey, employs more than 17,000 professionals throughout the country. At Sanofi, we work for what really matters: Health.
85 articles with Sanofi US
-
BioSpace takes an in-depth look at the Top 25 of Q1.
-
Cold Agglutinin Disease Associated with Greater Than Twofold Increased Risk of Mortality in First Five Years After Diagnosis
6/18/2018
New study is first to identify an increased risk of death in people with cold agglutinin disease compared to the general population
-
Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel
6/18/2018
Mr. Coppola previously held related positions at Sanofi.
-
Canadian science prodigy winner of prestigious international competition
6/8/2018
Sajeev Kohli, a Grade 11 student from Waterloo, Ontario, receives top honours in the Global Healthcare Challenge
-
FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes
5/22/2018
The U.S. Food and Drug Administration (FDA) has accepted Sanofi's regulatory filing for Zynquista (sotagliflozin).
-
Bioverativ and Sangamo Announce FDA Acceptance of IND Application for Gene-Edited Cell Therapy BIVV003 to Treat Sickle Cell Disease
5/16/2018
BIVV003 is a gene-edited cell therapy candidate for the treatment of people with sickle cell disease
-
Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis
5/16/2018
U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018
-
The Digital Therapeutics Alliance Announces New Members
5/8/2018
The Digital Therapeutics Alliance (DTA) welcomes nine companies to membership
-
Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients
5/1/2018
Sanofi and Regeneron Pharmaceuticals, Inc. announced they will lower the net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access from Express Scripts.
-
Regeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients
5/1/2018
Regeneron Pharmaceuticals, Inc. and Sanofi today announced they will lower the net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access from Express Scripts.
-
Innovative Targeting Solutions Announces Antibody Research Collaboration with Sanofi
5/1/2018
Innovative Targeting Solutions Inc., (ITS) the global leader in the discovery and optimization of antibodies, today announced a research collaboration with Sanofi.
-
Berkeley Lights' Announces New Agreement With Sanofi for Beacon® OptoFluidic Platform
4/19/2018
Berkeley Lights, Inc. (BLI) announced today Sanofi purchased the Beacon platform to accelerate their cell line development (CLD) process.
-
Bioverativ Highlights the Impact of Humanitarian Aid in Hemophilia
4/17/2018
More than 15,000 people with hemophilia in 40 developing countries have already been treated following Bioverativ and Sobi’s unprecedented donation of factor therapy to the WFH Humanitarian Aid Program
-
According to HBM Partners, a healthcare investing firm, out of the drugs approved over the last five years, 63 percent originated at smaller companies.
-
New survey reveals many misconceptions exist about allergies, illustrating the need for greater education
3/27/2018
Sanofi teams up with television personality Adam Savage and allergist Dr. Neeta Ogden to help dispel common allergy misconceptions with facts
-
FDA approves Toujeo® Max SoloStar®
3/27/2018
Max SoloStar holds more insulin than any other long-acting insulin pen
-
For the second time Ablynx’s anti-IL-6R Nanobody, vobarilizumab has failed to pass muster. This morning Belgium-based company said vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.
-
Sanofi and Regeneron have cut deals to dramatically reduce the price of their new cholesterol drug Praluent.
-
Seven months after Prevail Therapeutics launched, the company has secured $75 million in Series A financing to support the development of gene therapies for Parkinson’s disease.
-
Esperion announced that its bempedoic acid for lowering LDL-C cholesterol had positive results in a Phase III clinical trial.